Results 211 to 220 of about 403,834 (312)

Carrier‐Free Stimulus‐Responsive Theranostic Nanoprodrug Enabling GSH‐Consumption‐Promoted Chemo‐Photodynamic Cancer Therapy

open access: yesAdvanced Science, EarlyView.
Leveraging the critical role of glutathione (GSH) in mediating drug resistance and scavenging reactive oxygen species (ROS) in cancer cells, a carrier‐free GSH‐consuming theranostic nanoprodrug, consisting of a BODIPY photosensitizer and the chemotherapeutic drug paclitaxel linked through a GSH‐consuming drug linker, is developed to deeply explore the ...
Hansheng Huang, Binglin Sui
wiley   +1 more source

Interferon-λ signaling to maternal dendritic cells protects against congenital Zika virus infection. [PDF]

open access: yesSci Adv
Dedloff MR   +8 more
europepmc   +1 more source

Niche‐Mediated Neural Priming Enables Robust and Scalable Generation of Human Choroid Plexus Organoids

open access: yesAdvanced Science, EarlyView.
Compared to E8, mTeSR1 culture downregulated WNT and TGF‑β signaling, and upregulated neural differentiation pathways, enhancing neural priming. Under skin organoid induction conditions, mTeSR1‑cultured hESCs generated organoids with significantly higher neuroepithelial differentiation.
Zhongliang Chen   +7 more
wiley   +1 more source

Changes in active DNA demethylation pathway components during neoadjuvant chemotherapy and their prognostic significance in breast cancer. [PDF]

open access: yesBreast Cancer Res
Guz J   +9 more
europepmc   +1 more source

D4F‐Functionalized Ceria Nanozyme‐CasRx Platform Suppresses STING and Reprograms the Renal Immune Niche in Acute Kidney Injury

open access: yesAdvanced Science, EarlyView.
D4F‐functionalized ceria nanozyme–CasRx nanoparticles preferentially target renal macrophages through SR‐B1‐mediated uptake in ischemia–reperfusion injury. Ceria scavenges excessive ROS, while CasRx silences STING signaling, shifting macrophages toward a less inflammatory, pro‐resolving state and increasing the proportion of regulatory T cells.
Weibo Chen   +11 more
wiley   +1 more source

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

open access: yesAdvanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy